Orion And Marinus End Ganaxolone Agreement In Europe

Orion Corporation and Marinus Pharmaceuticals have mutually agreed to terminate their marketing and distribution agreement for ganaxolone in Europe. As a result, Marinus will regain the commercial rights for ganaxolone in Europe, where it is approved for the treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2 to 17. CDD is a rare and severe genetic condition. Orion will suspend all activities related to ganaxolone in Europe, including plans to launch the product.

Orion has decided to focus its efforts on oncology and pain management. He believes returning the European rights to Marinus is the best way to ensure the product reaches the patients who need it globally. As part of the agreement termination, Marinus will pay Orion EUR 1.5 million in the first half of 2025 to regain the commercial rights to ganaxolone. In 2021, Orion paid EUR 25 million for these rights. Following the termination, Orion will report a EUR 23.5 million write-down in its Q4 2024 financial results.